

PTO
JC715 U.S. PTO
10/29/99

LAW OFFICES
LERNER, DAVID, LITTBENBERG, KRUMHOLZ & MENTLIK, LLP

A

10/29/99
09/431546 PTO

600 SOUTH AVENUE WEST

WESTFIELD, NEW JERSEY 07090-1497

(908) 654-5000

FAX. (908) 654-7866

PATENTS, TRADEMARKS AND COPYRIGHTS

October 29, 1999

JOHN P. MALDIJAN
THOMAS M. PALISI
STEPHEN F. ROTH
KIMBERLY V. PEREZ
JASON I. GARBELL
RENEE M. ROBESON
BRIAN K. JOHNSON
LYNNE A. BORCHERSA
PETER A. CICALA
MICHAEL J. DOHERTY
MICHAEL J. WALLACE, JR.

OF COUNSEL
LAWRENCE I. LERNER
DANIEL H. BOBIS
RAYMOND W. AUGUSTIN
HARVEY L. COHEN
JEFFREY S. DICKEY

*NORTH CAROLINA BAR ONLY
▲ NEW YORK BAR ONLY
■ NEW YORK, CONNECTICUT
AND DISTRICT OF
COLUMBIA BARS ONLY

SIDNEY DAVID
JOSEPH S. LITTBENBERG
ARNOLD H. KRUMHOLZ
WILLIAM L. MENTLIK
JOHN R. NELSON
ROY H. WEPPNER
STEPHEN B. GOLDMAN
CHARLES P. KENNEDY
PAUL H. KOCHANSKI
MARCUS J. MILLET
BRUCE H. SALES
ARNOLD B. DOMPIERI
KEITH E. GILMAN
ROBERT B. COHEN
MICHAEL H. TESCHNER
GREGORY S. GEWIRTZ
JONATHAN A. DAVID
SHAWN P. FOLEY*

BOX PATENT APPLICATION
Assistant Commissioner For Patents
Washington, D.C. 20231

File No.: INTERLINK 3.0-003

Inventor(s): NICHOLAS P. EVERETT, QUINGSHUN LI,
CHRISTOPHER LAWRENCE, and H. MAELOR DAVIES

Title : PEPTIDES WITH ENHANCED STABILITY TO PROTEASE DEGRADATION

Assignee :

Dear Sir:

Enclosed herewith please find the following documents in the above-identified application for Letters Patent of the United States, which claims the benefit of Provisional Application Serial No. 60/106,373 and 60/106,573, filed October 30, 1998 and November 2, 1998, respectively:

1 Pages of Abstract
54 Pages of Specification
48 Number of Claims
3 Sheets of Drawings A4 11"

Declaration
One (1) return-addressed postcard
PLEASE PROVIDE FILING DATE AND SERIAL NUMBER

Assignment and Recordation Form Cover Sheet

Please charge Deposit Account No. 12-1095 in the amount of \$1810.00, calculated as follows:

Basic Fee	\$ 760.00
-----------	-----------

Additional Fees:

Total number of claims (including multiple dependent claims):	48	
Total number of claims in excess of 20:	28 x \$18	504.00
Number of independent claims:	10	
Number of independent claims minus 3:	7 x \$78	546.00
Fee for multiple dependent claim(s) (\$260)		0.00


TOTAL FILING FEE	\$ 1810.00
-------------------------	------------

CONVENTION DATE: for Appln. S.N. is claimed.
Priority Document: Enclosed Will follow

In the event the actual fee is greater than the payment authorized above, the Patent Office is authorized to charge any deficiency to our Deposit Account No. 12-1095.

Respectfully submitted,

LERNER, DAVID, LITTBENBERG,
KRUMHOLZ & MENTLIK, LLP


JASON I. GARBELL

Reg. No. 44,116

LB (LBEXCP) 98075 226891_1.DOC

EXPRESS MAIL LABEL NUMBER:

EM563239127US

PEPTIDES WITH ENHANCED
STABILITY TO PROTEASE DEGRADATION

The present application claims the benefit of
5 United States Provisional Patent Application
Nos. 60/106,373 and 60/106,573, filed October 30, 1998 and
November 2, 1998, respectively, the disclosures of which
are hereby incorporated by reference herein.

FIELD OF THE INVENTION

10 The present invention relates to antimicrobial peptides which are resistant to proteases and which have the ability to reduce the extent of protease degradation of peptides, polypeptides and proteins in plants.

BACKGROUND OF THE INVENTION

15 Antimicrobial peptides are produced by a wide range of organisms as part of their defense against infection. See Hancock & Lehrer, 1998, TIBTECH, 16:82-88; Everett, 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, Menn & Hollingworth, ACS
20 Symposium Series 551, pp. 278-91. Examples of such peptides include cecropins, attacins and diptericins which are involved in cell-free immunity in insects, the apidaecins from honeybees, the defensins from mammalian phagocytes, and the magainins from frog skin. Plants also
25 produce certain classes of antimicrobial peptides which are thought to play a role in resistance to microbial

plant pathogens. See Broekaert et al., 1997, Critical Reviews in Plant Sciences, 16:297-323.

Plants have been genetically engineered to produce antimicrobial peptides, both natural and synthetic 5 to increase resistance to disease. See Jaynes et al., 1987, BioEssays, 6:263-70; Hancock and Lehrer, 1998, TIBTECH, 16:82-88. Unfortunately, this approach has met with very limited success. Either the amount of peptide produced by the transgenic plant is too small and/or the 10 plants are no less susceptible to infection by plant pathogens. See Hancock and Lehrer, 1998, TIBTECH, 16:82-88. A major limitation to the expression of foreign peptides in transgenic plants is due to the susceptibility of the foreign peptides to rapid degradation by proteases. 15 For example, transgenic potato cultivars which express a gene encoding the antimicrobial peptide cecropin B at levels up to 0.6% of total mRNA produce no detectable cecropin B peptide and no improvement in resistance to potato soft rot. See Sjefke et al., 1995, American Potato Journal, 72:437-45. Similar studies in tobacco have demonstrated that expression of cecropin B genes also does not result in detectable cecropin B peptide levels and resistance to bacterial infections. See Florack et al., 1995, Transgenic Research 4:132-41. Studies have also 20 shown that cecropin B and antimicrobial peptides related to magainins are rapidly degraded by proteases in the 25

intercellular fluid of plant leaves. See Mills et al., 1994, Plant Science, 104:17-22 and Everett, 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, Menn & Hollingworth, ACS Symposium Series 551, pp. 5 278-91.

One proposed solution to the problem of peptide instability due to protease degradation has been to identify the protease-sensitive sites within a particular peptide and to design amino acid substitutions that 10 increase the stability of peptides to plant proteases while retaining the antimicrobial activity of the peptides. This approach resulted in a synthetic magainin derivative having the amino acid sequence Met-Gly-Ile-Gly-Lys-Phe-Leu-Arg-Glu-Ala-Gly-Lys-Phe-Gly-Lys-Ala-Phe-Val- 15 Gly-Glu-Ile-Met-Lys-Pro that had enhanced stability against proteases found in the intercellular fluid of plant tissues and was therefore an improved candidate for use in or on plants. See Everett, 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, 20 Menn & Hollingworth, ACS Symposium Series 551, pp. 278-91; U.S. Patents Nos. 5,424,395 and 5,519,115.

Another proposed solution to the problem of peptide instability has been to produce the reverse- or retro-analogs of natural antimicrobial peptides or their 25 synthetic derivatives. See U.S. Patent No. 5,519,115, and

Merrifield et al., 1995, PNAS, 92:3449-53. Such reverse-peptides retain the same general three-dimensional structure (e.g., alpha-helix) as the parent peptide except for the conformation around internal protease-sensitive sites and the characteristics of the N- and C-termini.
5 Reverse peptides are purported not only to retain the biological activity of the non-reversed "normal" peptide but may possess enhanced properties, including increased antibacterial activity and reduced hemolysis. See Iwahori et al., 1997, Biol. Pharm. Bull. 20:267-70.

10 Indolicidin, having the amino acid sequence Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg, is a potent antimicrobial tridecapeptide. It was originally purified from cytoplasmic granules of bovine neutrophils.
15 See Selsted et al., 1993, J. Biol. Chem., 267:4292-95. It is a member of a class of proline-rich peptides that have been recovered from the leukocytes of different mammals, a marine invertebrate and insect haemolymph. See Hancock and Lehrer, 1998, TIBTECH, 16:82-88. The
20 antimicrobial potencies of natural and synthetic indolicidin are identical. See Van Abel et al., 1995, Int. J. Protein Res. 45:401-09. The mode of antibacterial action of indolicidin has been reported to be based on the disruption of the cytoplasmic membrane by channel formation.
25 See Falla et al., 1996, J. Biol. Chem. 32:19298-303. More recently, it has been suggested that

membrane permeabilization is likely to occur due to deformation of the membrane surface rather than formation of transmembrane channels by indolicidin and its analogs.

See Subbalakshmi et al., 1998, J. Biosci., 23:9-13.

5 Numerous analogs of indolicidin have been synthesized and tested in attempts to evaluate the requirements for antimicrobial and hemolytic activities, and to increase activity. Subbalakshmi et al. (FEBS Letters 395:48-52 (1996)) reports that peptides in which
10 proline was replaced by alanine and tryptophan was replaced by phenylalanine exhibit antibacterial activities comparable to that of indolicidin. The replacement of tryptophan by phenylalanine, however resulted in a loss of hemolytic activity. Falla and Hancock (Antimicrobial Agents and Chemotherapy, 41:771-75 (1997)) tested a
15 synthetic peptide, CP-11, Ile-Leu-Lys-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg, based on indolicidin, which was designed to increase the number of positively charged residues, maintain the short length (13 amino acids), and enhance
20 the amphipathicity relative to indolicidin. They found that CP-11 had better activity against *E. coli*, *Pseudomonas aeruginosa*, and *Candida albicans*, but reduced activity against *Staphylococcus aureus*. Lim et al. (J. Biochem. Mol. Biol. 30:229-33 (1997)) tested the effects
25 of substituting certain tryptophan, proline or arginine residues in indolicidin. Substitutions of some tryptophan

residues by isoleucine or glycine were tolerated but substitution of Pro⁷ with alanine significantly reduced activity against *E. coli*. Substitutions of either Arg¹² or Arg¹³ with alanine also reduced biological activity.

5 SUMMARY OF THE INVENTION

Applicants have discovered that indolicidin exhibits remarkable resistance to proteolysis by proteases. Applicants have also discovered that Rev4, the reverse peptide of indolicidin, and derivatives and analogs of indolicidin and Rev4 share these properties while maintaining antimicrobial properties. Applicants have further discovered that exogenous or non-native peptides, polypeptides and proteins of agronomic interest (hereinafter "proteins of agronomic interest") exhibit greater resistance to degradation by multiple classes of proteases that have different active sites and substrate specificities in the presence of indolicidin, Rev4 and related structures.

One aspect of the present invention is directed to an isolated and purified peptide which is, includes, or consists essentially of Rev4, or a functional equivalent thereof that exhibits antimicrobial properties and/or renders other proteins applied to and/or produced by plants more resistant to proteolytic degradation. This aspect of the present invention also entails nucleic acids

including or consisting essentially of sequences encoding Rev4, and nucleic acid constructs such as vectors containing the Rev4-encoding sequence. Recombinant cells such as plants and bacteria (e.g., *Agrobacterium tumefaciens*) and protoplast containing the Rev4-encoding sequence are also entailed. Transgenic plants that express Rev4-encoding nucleic acids exhibit increased resistance to microbial pathogens that infect plants.

Transgenic plants can be made in accordance with standard techniques including regenerating plants from transformed protoplasts or transformed plant tissue. Yet another embodiment of this aspect of the invention relates to seeds derived from the transgenic plants. In yet another embodiment, increased resistance to microbial infection may be imparted to a given plant species by applying to the plant a composition containing the Rev4 protein or functional equivalent thereof. These compositions may be in the form of a dry powder or a liquid dispersion suitable for spraying, etc.

Another aspect of the present invention is directed to a method of decreasing the extent of or inhibiting proteolytic degradation of a non-native protein susceptible to proteolytic degradation, on or in a plant. The method entails administering to a plant indolicidin, Rev4 or a functional equivalent thereof, before simultaneously with, or after the administration of a non-

native protein of interest, such as an anti-pathogenic protein. The "administration" of the Rev4 or indolicidin as in the case of the Rev4-containing compositions, above, may be accomplished by direct application to the plant or
5 by genetic engineering techniques whereby a transgenic plant is produced. In the case of transgenics, the non-native construct containing the Rev4 or indolicidin may be constructed so as to be expressed before, during or suitably after expression of the non-native DNA encoding
10 the non-native protein of interest. This method may also be described in terms of a method of preserving or increasing the activity of a given non-native protein applied to or produced by a plant, the non-native protein being susceptible to proteolytic degradation. In
15 preferred embodiments, transgenic plants contain recombinant nucleic acid molecules containing a first sequence encoding Rev4, indolicidin, or a functional equivalent thereof, and a second sequence encoding the protein of interest.

20 One aspect of the present invention is directed to synthetic peptides comprising Rev4 having the amino acid sequence Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile ("Rev4"), and analogs and derivatives of Rev4 that exhibit antimicrobial and anti-proteolytic properties,
25 nucleic acids encoding these peptides, as well as nucleic acid constructs, vectors and hosts containing the nucleic

acids are also disclosed.

Another aspect of the present invention provides a method for increasing resistance of peptides, polypeptides and proteins of agronomic interest to degradation or inactivation by proteases or reducing the extent of protease degradation. In preferred embodiments, DNAs encoding the peptides of the present invention are co-expressed with another non-native nucleic acid encoding an antifungal, antibacterial, antiviral and insecticidal protein, or any other preferred proteins of interest are beneficial to the plant and/or impart resistance to plant disease and pathogens.

The present invention also provides nucleic acids and genetic constructs comprising sequences that encode Rev4 and biologically functional equivalents thereof, and methods for inserting such nucleic acid sequences and genetic constructs into host cells for the production of the peptides encoded thereby.

Transgenic plants, parts or cells thereof, and seed derived from the plants are also included.

The present invention also provides recombinant microorganisms and protoplasts containing nucleic acid sequences that encode the peptides according to the present invention.

The present invention also provides antipathogenic compositions, comprising at least one of the peptides of the present invention along with at least one antifungal, antibacterial, antiviral or insecticidal agent.

The compositions of the present invention also include recombinant host cells, such as bacterial (e.g., *agrobacterium tumefaciens*) and fungal cells, which produce the peptides of the present invention and at least one antipathogenic protein. In preferred embodiments, the compositions are applied to roots and/or leaves. The cells colonize the roots and/or leaves of plants.

DESCRIPTION OF THE FIGURES

Fig. 1 is gene construct RIL which includes a nucleic acid sequence encoding Rev4

Fig. 2 is graph depicting the stability of Rev4 and related structures to proteolysis.

Fig. 3 is graph depicting bacterial pathogen resistance of transgenic plants containing Rev4.

20 DETAILED DESCRIPTION OF THE INVENTION

The contents of each of the publications discussed in this specification, including the references cited therein, are herein incorporated by reference in

their entirety.

The phrase "functional equivalent peptide" is meant to include peptide, polypeptide, and protein derivatives and analogs of indolicidin and Rev4 that exhibit sequence similarity to indolicidin and Rev4, and which exhibit the same or similar antimicrobial activity and/or ability to increase the resistance of other proteins to degradation or inactivation by proteases. These properties may be determined by the methods described in Examples 7-13 of the specification.

Functional equivalent peptides also include amino acid sequences containing conservative amino acid changes in the sequence. In such amino acid sequences, one or more amino acids in the fundamental sequence is substituted with another amino acid or amino acids, the charge and polarity of which is similar to that of the native amino acid, i.e., a conservative amino acid substitution resulting in a silent change. The amino acids may include any of the D-amino acids corresponding to the 20 L-amino acids commonly found in proteins, imino amino acids, rare amino acids, such as hydroxylysine, or non-protein amino acids, such as homoserine and ornithine. A peptide may have none, one, or more of these derivatives and D-amino acids.

Substitutions, additions, deletions and non-

naturally occurring derivatives of amino acid residues are also within the scope of functional equivalent peptides of present invention.

Amino acid substitutions within the fundamental 5 polypeptide sequences are preferably selected from other members of the class to which the naturally occurring amino acid belongs. See Table 1. Amino acids are typically be divided into the following four groups: (1) acidic amino acids; (2) basic amino acids; (3) neutral 10 polar amino acids; and (4) neutral non-polar amino acids.

Conservative amino acid changes within the fundamental polypeptide sequence are made by substituting one amino acid within the same group.

TABLE 1: PREFERRED AMINO ACID SUBSTITUTIONS

Arg	Trp	Pro	Lys	Leu	Ile
Lys	Gly	Trp	Arg	Pro	Pro
His	Ala	Glu	His	Trp	Trp
	Val	Ala		Gly	Gly
	Leu	Val		Ala	Ala
	Ile	Leu		Val	Val
	Pro	Ile		Ile	Leu
	Phe	Phe		Phe	Phe
	Met	Met		Met	Met
	Lys	Lys		Lys	Lys

15 Preferred equivalents of indolicidin and Rev4 are represented by the following sequences:

(1) Y-Y-Y-X-Y-Y-Y-Y-X-X

(2) X-X-Y-Y-Y-Y-X-Y-Y-Y

wherein each X is independently arginine, lysine or histidine and each Y is independently tryptophan,
5 glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.

In other preferred embodiments, the functional equivalent proteins contemplated herein possess about 70% or greater sequence similarity, more preferably about 80%
10 or greater sequence similarity, and most preferably about 90% or greater sequence similarity.

The modification of any of the peptide residues in the sequence, including the N- or C-terminal residues, is also within the scope of this invention. The peptides
15 may be altered by chemical or biological means, such as, for example, methylation and amidation, and alteration of amino acid sides chain, such as acylation. The peptides may also be labeled, such as with a radioactive label, a fluorescent label, a mass spectrometry tag, biotin and the like.
20 The peptides may also include additions of amino acids to the N- and C-termini. For example, a glycine residue may be added to the C- terminus to provide a precursor for C-terminal amidation. See Bradbury, A.F. and Smyth, D.G., 1991, TIBS 16:112.

The peptides may also be conjugated, fused, or crosslinked to the protein of interest. Examples of include Ser-Rev4-OH comprising the amino acid sequence Ser-Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile 5 and Rev4-C-fusion comprising the amino acid sequence Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile-Gly-Gly-Gly-Tyr-Asp-Pro-Ala-Pro-Pro-Pro-Pro-Pro.

The peptides of the present invention may be synthesized in accordance with standard techniques, 10 including, but not limited to, chemical synthesis, synthesis by automated procedure, synthesis in heterologous biological systems such as microbial, plant and animal systems, tissue cultures, cell cultures, or in vitro translation systems. For example, the peptides may 15 be synthesized using standard solid-phase Fmoc protection strategy with HATU as the coupling agent. Other synthesis techniques include the t-Boc protection strategy and the use of different coupling reagents.

The present invention also includes nucleic acid 20 sequences comprising or consisting essentially of sequences that encode peptides of the present invention. Nucleic acid sequences include DNA, RNA, genomic DNA, mitochondrial DNA, chloroplast DNA, plasmid DNA, cDNA, synthetic DNA, and mRNA nucleotide sequences.

25 The present invention also comprises nucleic

PCT/US2012/059000

acid constructs comprising the nucleic acids of the present invention and methods for inserting such nucleic acids into host cells. Preferably, the nucleic acid constructs contain a promoter sequence and a sequence 5 encoding Rev4 or a functional equivalent thereof. The nucleic acid sequences can be inserted into a variety of host systems suitable for production of the peptide, including, for example, microorganisms, fungi and plants. Examples of promoters suitable for use in the present 10 invention include broad expression promoters such as CaMV and Brassica ALS3, tissue/cell-type specific promoters such as the maize ZRP2; pathogen induced promoters such as HMG2 and tobacco hsr203J; pest/wound inducible promoters such as potato pin II, potato wun 1, and poplar Win6; 15 stress inducible promoters such as *Arabidopsis rd29A* and *Arabidopsis adh*; and chemically induced promoters such as wheat Em, soybean GH3, and potato CDI.

Other regulatory sequences may also be included in the construct. Such sequences include, without 20 limitation, an enhancer, repressor, ribosome binding site, transcription termination signal sequence, secretion signal sequence, origin of replication, selectable marker, and the like. The regulatory sequences are operationally associated with one another to allow transcription and 25 subsequent translation.

Reporter genes may also be included in the construct in order to monitor transcription and translation. In preferred embodiments, the nucleic acid sequence encoding Rev4 or a functional equivalent is 5 introduced into a plant using an expression vector. Many expression vectors have been developed for the production of recombinant plants, including bacteria, plasmids and viruses. Plant viral vectors suitable for the present invention include, for example, those disclosed in U.S. 10 Patent No. 5,316,931. The proteins and nucleic acids of the present invention are administered to a plant. Transgenic plants expressing Rev4 exhibit resistance to infection by microbial plant pathogens.

In another embodiment, transgenic plants produce 15 both indolicidin or Rev4 and another non-native protein. The transgenic plants are produced by preparing a plant having a genome that contains the DNA sequence encoding indolicidin, rev4 or functional equivalents thereof which are expressed. Preferably the transgenic plant is prepared 20 by stably transforming a protoplast with the DNA sequence encoding indolicidin, rev4 or functional equivalents thereof. The transgenic plant may also be prepared by introducing and regenerating the plant from plant tissue containing the DNA molecule.

25 Preferably, the peptides of the present invention are co-expressed with antibacterial, antifungal,

PCT/US2013/037450

antiviral and/or insecticidal proteins, proteins of agronomic interest include proteins derived from *Bacillus thuringiensis* (B.t.), other *Bacillus* species, or *Photorhabdus* or *Xenorhabdus* species; proteins involved in 5 improving the quality of plant products or agronomic performance of plants, as well as peptides or proteins that are to be produced in plants for the purpose of extraction and use as pharmaceutical products, agricultural products, feed or food additives, industrial 10 enzymes; peptides or proteins that cause an alteration in plant metabolism that leads to the production of metabolites that can be extracted and used as pharmaceutical products, feed and food additives, agricultural products such as fungicides or insecticides, 15 and specialty chemicals or chemical intermediates that have commercial value.

In more preferred embodiments, the transgenic plants co-produce the indolicidin or Rev4 and Magainins, reverse Magainins, PGLc, reverse PGLc, PI's, reverse PI's, 20 Cecropins, reverse Cecropins, Sarcotoxins, reverse Sarcotoxins, Bombinins, reverse Bombinins, XPFs, reverse XPF's, Thionins, reverse Thionins, Defensins, reverse Defensins, Melittins, reverse Melittins, PGL a, and reverse PGLa, Dermaseptins, reverse Dermaseptins, 25 Histatins, reverse Histatins, peptides derived from pig myeloid cells, peptides derived from human neutrophil

cathepsin G, antimicrobial peptides from bovine neutrophils, Seminalplasmin, antimicrobial derived from Lactoferrin, Drosocin, Tachyplesins, reverse Tachyplesins, Maize Basic Peptide I, Tracheal antimicrobial peptides,
5 Antimicrobial peptides from seeds of amaranth, antimicrobial peptides from seeds of *Mirabilis jalapa*, Ranalexin, Brevenin, Subtilin, Nisin, Epidermin, Lactacin 481, and basic amphipathic peptides.

The co-production of a peptide that can protect
10 a second protein from degradation or inactivation by proteases found in or on plants is advantageous in many different situations. For example, if the second protein has antifungal, antibacterial, antiviral or insecticidal activity, but is susceptible to degradation or
15 inactivation by plant proteases, the present invention enables the use of multiple antimicrobial proteins that exploit more than one mode of action to protect plants against disease caused by pathogens. This co-production thus reduces the possibility of developing resistant
20 strains of pathogens, broaden the scope of plant disease resistance, and results in synergistic control of plant pathogens. If the second peptide, polypeptide or protein is susceptible to degradation or inactivation by proteases endogenous to an invading plant pathogen, the use of the
25 present invention may increase the range of pathogens against which a particular anti-pathogenic protein is

active. Thus, because of the remarkable stability of the peptides to degradation or inactivation by the complex mixture of proteases present in whole cell extracts of plant tissues, the present invention may be particularly
5 useful in maintaining antimicrobial activity in plant tissues that have been damaged by insects or post-harvest handling.

Similarly, potentially labile proteins may be protected from undue protease degradation or inactivation
10 during extraction from plant tissues. If the second protein is insecticidal, the present invention provides a mechanism by which the insecticidal protein is stabilized against plant proteases and that it accumulates to higher concentrations in healthy plant tissues and survive
15 additional proteases, of plant or insect origin, encountered during insect feeding. For protection of feed, food and other products from spoilage caused by insects or microorganisms, the indolicidin and Rev4 peptides do not have to be produced by a plant part that
20 is a component of the feed, food or other product. The peptide may be added during post-harvesting processing and formulation.

Plants suitable for expression or application of the peptides disclosed in the present invention include
25 flowering plants, and preferably, crop plants, e.g.,

monocots and dicots. More preferred include maize, tomato, turfgrass, asparagus, papaya, sunflower, rye, beans, ginger, lotus, bamboo, potato, rice, peanut, barley, malt, wheat, alfalfa, soybean, oat, eggplant, squash, onion, 5 broccoli, sugarcane, sugar beet, beets, apples, oranges, grapefruit, pear, plum, peach, pineapple, grape, rose, carnation, daisy, tulip, Douglas fir, cedar, white pine, scotch pine, spruce, peas, cotton, flax, coffee and tobacco.

10 The present invention also encompasses the use of nucleic acid sequences or constructs encoding indolicidin or Rev4 to produce recombinant vectors, for example, plasmids, recombinant microorganisms, probes, and primers useful in identifying related nucleic acid 15 sequences that encode peptides that confer resistance to plant disease and which confer stability to peptides, polypeptides, and proteins. The peptides may be synthesized by recombinant production using various host systems, including bacteria, yeast, insect, and mammalian 20 cells.

 The present invention also provides antipathogenic compositions comprising indolicidin or Rev4 along with at least one other antifungal, antibacterial, antiviral or insecticidal protein. The compositions can 25 be formulated by conventional methods using any suitable

carrier. Other ingredients such as inert materials, surfactants, solvents, and other additives, which are well known in the art, may be added to the compositions. The compositions may also be combined with fertilizers, 5 insecticides, antifungal agents, attractants, sterilizing agents, acaricides, nematodes, and herbicides.

Preferably, the indolicidin or Rev4 is applied in a concentration in the range from about 1 $\mu\text{g}/\text{ml}$ to about 50 $\mu\text{g}/\text{ml}$ to obtain antimicrobial activity and in a 10 concentration in the range of from about 1 $\mu\text{g}/\text{ml}$ to about 100 $\mu\text{g}/\text{ml}$ to protect other peptides, polypeptides, and proteins from protease degradation.

The compositions of the present invention also include those in the form of recombinant host cells, such 15 as bacterial and fungal cells, that produce indolicidin or Rev4 and colonize roots and/or leaves of plants. The protease-inhibiting peptides of this invention can be used in various combinations with each other to obtain synergistic activity and/or to provide broader protection 20 against multiple classes of proteases having different active sites and substrate specificity. For example, Rev4 may be combined with another peptide from the indolicidin/Rev4 family of protease-inhibiting peptide which exhibits increased activity in protecting a 25 particular class of peptide, polypeptide or protein or

which exhibits increased activity against a particular protease.

The detailed description of the invention has been provided to aid those skilled in the art in practicing the present invention. The detailed description should not be construed to unduly limit the present invention as modifications and variations in the embodiments discussed herein may be made by those of ordinary skill in the art without departing from the scope of the present discovery. The present invention can be better understood from the following illustrative, non-limiting examples.

EXAMPLE 1

Chemical Synthesis and Purification of Rev4 (amide)

Peptides of the type described in this invention can be synthesized and purified by standard techniques as discussed in detail in U.S. Patents Nos. 5,424,395 and 5,519,115. For convenience, they may also be purchased from one of many companies that offer custom peptide synthesis. One such company is Genosys Biotechnologies, Inc., P.O. Box 41027, Houston, TX 77240 (Tel: 281-363-3693). Synthesis of the C-terminal amide form of Rev4 peptide (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) was contracted with Genosys Biotechnologies Inc.

HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak
5 eluting after 24.548 minutes.

EXAMPLE 2

Chemical Synthesis and Purification of Indolicidin

Synthesis of the C-terminal amide form of indolicidin (Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg) was contracted with Genosys Biotechnologies Inc.
10 HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak
15 eluting after 23.232 minutes.

EXAMPLE 3

Chemical Synthesis and Purification of Ser-Rev4

Synthesis of a non-C-terminal amide analog of Rev4 in which an extra Ser was added to the N-terminus
20 (Ser Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a

Case 20000000000000000000000000000000

flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 22.363 minutes.

EXAMPLE 4

5 Chemical Synthesis and Purification of Rev4-C-Terminal Fusion Peptide

Synthesis of a Rev4 with a C-terminal extension of 13 amino acids (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile Gly Gly Tyr Asp Pro Ala Pro Pro Pro Pro 10 Pro Pro) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak 15 eluting after 21.213 minutes.

EXAMPLE 5

Chemical Synthesis and Purification of Indolicidin F (amide)

Synthesis of a C-amidated indolicidin in which 20 the Trp residues were replaced with Phe (Ile Leu Pro Phe Lys Phe Pro Phe Phe Pro Phe Arg Arg) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of

acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 20.415 minutes.

EXAMPLE 6

5 Chemical Synthesis and Purification of Indolicidin F-P
(amide)

Synthesis of a C-amidated derivative of indolicidin in which the Trp residues were replaced by Phe and a Pro residue was deleted (Ile Leu Lys Gly Phe Pro Gly 10 Phe Pro Arg Arg Lys) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with 15 a single peak eluting after 15.527 minutes.

EXAMPLE 7

Stability of Reverse Peptides to Proteases Present in Plant Extracellular Fluid (ECF)

The stability of various reverse peptide 20 versions of naturally occurring peptides was determined by incubating the reverse peptides with various dilutions of ECF and then measuring by HPLC analysis the percentage of parent peptide remaining at the end of the incubation

PCT/US2003/020000

period. See Fig. 2. ECF was obtained from tobacco leaves in accordance with the method described in U.S. Patent No. 5,424,395. Fifty micrograms of each peptide was incubated with different amounts of ECF in 50 mM Tris-HCl buffer, pH 7.5, total volume 50 microliters, for one hour at 37° C. The reaction was stopped by adding 1% trifluoroacetic acid (TFA). A sample of the reaction mixture (20 µL) was injected onto a Vydac C4 column (4.6x250 mm) in a Waters HPLC system with 515 pumps, 486 detector and Millennium software. The sample was eluted with a gradient of 0.1% TFA in water to 60% acetonitrile in 0.1% TFA. The area of the peak corresponding to the undigested peptide was integrated and compared with the equivalent peak from a 0% ECF control. The non-reverse peptide, MYP30 (Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro), was included as a reference. The ranking of peptide stabilities shown in Fig. 2 was Rev4 (reverse indolicidin; Arg Arg Trp Pro Trp Pro Trp Lys Trp Pro Leu Ile)>Rev6 (reverse PGLc; Leu Ala Lys Leu Ala Val Lys Ala Ile Lys Gly Ala Ile Ala Gly Ala Lys Ser Ala Met Gly)> Rev3 (reverse cecropin P1; Arg Pro Gly Gly Gln Ile Ala Ile Ala Ile Gly Glu Ser Ile Arg Lys Lys Ala Ser Asn Glu Leu Lys Lys Ala Thr Lys Ser Leu Trp Ser)>MYP30 (Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro)>Rev2 (reverse cecropin amide; Lys Ala Ile

Gln Thr Ala Gln Gly Val Val Ala Val Ala Pro Gly Ala Lys
Ile Ile Gly Asp Arg Ile Asn Gln Gly Val Lys Glu Ile Lys
Lys Phe Leu Lys Trp Lys) >Rev8 (reverse bobinin-like
peptide; Asn Ala Phe His Glu Ala Leu Gly Lys Ala Leu Gly
5 Lys Leu Ala Ser Lys Gly Ala Ser Leu Ile Ser Ala Gly Ile
Gly).

EXAMPLE 8

Stability of Rev4 to Proteases Present in Whole Cell Extract (WCE)

10 Whole cell extract (WCE) was prepared by grinding one gram of Kentucky 14 tobacco leaf tissue in liquid nitrogen, followed by extraction with 3 mL of 100 mM Tris-HCl buffer, pH 7.5, 50 mM NaCl. The mixture was clarified by spinning in a microcentrifuge (14,000 r.p.m.,
15 5 minutes). The supernatant (WCE) was kept frozen as aliquots at -80° C until required for an assay. Fifty micrograms of each peptide was incubated with different amounts of WCE in 50 mM Tris-HCl buffer, pH 7.5, total volume 50 microliters, for one hour at 37° C. The
20 reaction was stopped by adding 1% trifluoroacetic acid (TFA). A sample of the reaction mixture (20 µL) was injected onto a Vydac C4 column (4.6x250 mm) in a Waters HPLC system with 515 pumps, 486 detector and Millenium software. The sample was eluted with a gradient of 0.1%
25 TFA in water to 60% acetonitrile in 0.1% TFA. The area of

the peak corresponding to the undigested peptide was integrated and compared with the equivalent peak from a 0% WCE control. MYP 30 (Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro) is more susceptible to degradation by WCE than ECF, but Rev4 (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) is much more stable to WCE than either MYP30 or Magainin 2 (Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Asn Ser).

10 EXAMPLE 9

Ability of Rev4 to Protect Magainin 2 from Degradation by WCE

Assays for WCE protease degradation were performed as described in Example 8 except that one of the 15 samples represented Magainin 2 that was mixed with Rev4 before the addition of WCE. The amounts of Magainin 2 and Rev4 remaining in the mixture were determined by HPLC as described for Examples 7 and 8. Rev4 was able to confer on Magainin 2 a stability to WCE equal to that of Rev4 20 itself (Table 2).

% WCE	% Peptide Remaining Intact after 1 Hr.			
	Magainin 2	Rev 4	Magainin 2 in Rev4 + Magainin 2 Mix	Rev4 in Magainin 2 + Rev4 Mix
0	100	100	100	100
15	10.9	82.7	89.7	89.6
30	0.3	77.2	87.6	84.0
45	0.4	66.9	ND	ND
60	0.3	61.6	73.1	75.3

90	0.4	55.2	56.3	53.8
----	-----	------	------	------

ND = not determined

EXAMPLE 10

Ability of Rev4 to Protect Proteins From Degradation by Commercial Protease

5 The ability of Rev4 to inhibit four different classes of proteases was tested using fluorescent labeled casein as substrate under the following conditions:

Enzyme	Class	Enzyme Concentration (mg/mL)	Assay Buffer
Chymotrypsin	Serine Protease	0.01	5 mM Tris-HCl, pH8.0
Carboxypeptidase	Zinc Metalloprotease	0.10	5 mM Tris-HCl, pH8.0
Papain	Sulphydryl Protease	0.01	5 mM MES, pH6.2
Pepsin	Acid Protease	0.01	5 mM HCl, pH2.0

Each protease was incubated with substrate (5 μ g/mL fluorescent labeled casein; Molecular Probes Inc., Eugene, OR) and peptide in a total volume of 200 μ L in a 96-well microtiter plate. Before use, papain was activated with cysteine (Arnon, 1970, Methods in Enzymology 19:226-44). After incubation at room temperature for one hour, fluorescence due to casein digestion was measured in a Luminescence Spectrometer (LS50B, Perkin Elmer Ltd., England) with an excitation wavelength of 505 nm and an emission wavelength of 513 nm. The blank control contained the substrate, buffer and

10
15

peptide but lacked the protease. Under these conditions, Rev4 was found to inhibit chymotrypsin, carboxypeptidase and papain, but not pepsin (Table 3).

Protease	% Inhibition of Proteolysis by Rev4 at Various Concentrations (μ g/ml)							
	0	2.5	5	10	20	25	50	100
Chymotrypsin	0	16	42	75	97			
Carboxypeptidase	0	58	92	100	100			
Papain	0	29	72	93	99			
Pepsin	0					3	0	0

5 EXAMPLE 11

Antifungal Activity of Rev4

When subjected to blind testing by two independent research groups, Rev4 was identified to have broad spectrum activity against important plant pathogens 10 including *Cercospora* spp., *Colletotrichum* spp., *Fusarium* spp. and *Helminthosporium* spp.

Tobacco blue mold (*Peronospora tabacina*) was used to compare the antifungal activity of Rev4 with that of MYP30. Spores of *Peronospora tabacina* were harvested 15 from infected tobacco leaf with sterile water and washed three times. The spore suspension was diluted to 2,000 spores per mL. Peptide solution (2 μ L) was added to spore suspension (48 μ L) in a 96-well microtiter plate. After incubation in the dark at room temperature for 24 hours, 20 the number of germinated spores was determined

microscopically. Rev4 was found to be significantly more potent than MYP30.

Peptide	Concentration ($\mu\text{g/mL}$)	Spore Germination (%)
MYP30	0	71
	1	60
	5	28
	25	10
	50	0
Rev4	0	71
	1	46
	5	2
	25	0
	50	0

The antifungal activity of Rev4 and related peptides was also compared using two tomato pathogens,
5 *Verticillium dahliae race1* and *Alternaria alternata f.sp. lycopersici*. Spores were harvested from pure cultures grown on V8 medium, diluted to 5,000 spores per mL, and tested against dilution series of peptides in 96-well plates as described in U.S. Patent No. 5,424,395. The
10 minimum concentration required to completely inhibit spore germination for at least 48 hours was determined in triplicate:

Peptide SEQ. ID No.	<i>Verticillium dahliae</i>	<i>Alternaria alternata</i>
SEQ. ID No. 4	40 $\mu\text{g/ml}$	50 $\mu\text{g/ml}$
SEQ. ID No. 5	50 $\mu\text{g/ml}$	100 $\mu\text{g/ml}$
SEQ. ID No. 6	23 $\mu\text{g/ml}$	50 $\mu\text{g/ml}$
SEQ. ID No. 7	50 $\mu\text{g/ml}$	100 $\mu\text{g/ml}$

EXAMPLE 12

Antifungal Activity of Rev4-Related Peptides

15 The peptides described as SEQ. ID Nos. 4,5,6,7

and 8 in Examples 1, 3, 4, 5 and 6 were tested for antifungal activity as described in Example 11. All the Rev-related peptides showed significant inhibition of *Peronospora tabacina* spore germination when tested at a final 5 concentration of 2 µg/mL.

Peptide Treatment	% Germination (mean+/- sem)	% Control
None (control)	76.6 +/- 11.2	100
SEQ. ID NO. 4 (Rev4)	3.7+/-3.2	4
SEQ. ID NO. 5	6.8+/-6.3	9
SEQ. ID NO. 6	5.7+/-9.8	7
SEQ. ID NO. 7	8.8+/-5.4	11
SEQ. ID NO. 8	17.3+/-3.5	23

EXAMPLE 13

Ability of Rev4-Related Peptides to Protect a Protein Against Chymotrypsin

The peptides described in EXAMPLE 12 were tested 10 for their effects on the action of chymotrypsin on casein using the methods described in EXAMPLE 10. Peptides related to Rev4 but comprising amino acid extensions on either the N-terminus (Ser Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) or C-terminus (Arg Arg Trp Pro Trp 15 Trp Pro Trp Lys Trp Pro Leu Ile Gly Gly Gly Tyr Asp Pro Ala Pro Pro Pro Pro Pro) protected fluorescent-labeled casein from the action of chymotrypsin. Peptides related to indolicidin (Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg) in which Trp residues were replaced by Phe 20 (Ile Leu Pro Phe Lys Phe Pro Phe Phe Pro Phe Arg Arg; Ile

Leu Lys Gly Phe Pro Gly Phe Pro Arg Arg Lys) did not have this protective effect, even though they had retained antifungal activity (EXAMPLE 12).

Peptide Identity	Peptide Concentration (μ g/mL)	Chymotrypsin Activity (Fluorescence Units)	
		Mean	+/- s.e.m.
None (control)	0	375	58
SEQ. ID NO. 5	5	162	25
SEQ. ID NO. 5	20	44	18
SEQ. ID NO. 6	5	212	22
SEQ. ID NO. 6	20	45	6
SEQ. ID NO. 7	5	386	71
SEQ. ID NO. 7	20	385	13
SEQ. ID NO. 8	5	385	85
SEQ. ID NO. 8	20	321	68

EXAMPLE 14

5 Construction of a Gene ("RIL") Encoding Rev4 Peptide

A DNA sequence encoding Rev4 (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile, no C-terminal amide) was designed according to the standard genetic codon and the tobacco codon usage table (found at web site 10 <http://www.dna.affrc.go.jp>). Two oligonucleotide primers (AGGAGATGGCCTTGGTGGCCTTGGAAATGGCCTCTTATT and CCAGTCTCTAGAA CCATGAGGAGATGGCCTTGG) were used to make the full coding sequence to clone into expression vectors. Full-length DNA was generated by polymerase chain reaction (PCR: 15 Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory Press.). Taq DNA polymerase was purchased from Gibco BRL, and the reaction

set up as suggested by the manufacturer. No template was needed for the PCR reaction because the two primers have overlapping regions (15 nucleotides). To facilitate the gene cloning, two restriction sites (*Xba*I and *Sac*I) were 5 engineered on both ends of the gene and extra nucleotides were added to the ends to ensure these enzyme digestions.

The digested PCR product was cloned into pBluescript II KS+ (or pBS, Stratagene, LaJolla, CA) plasmid vector with 5' AMV sequence in the multiple 10 cloning site. The 5' AMV sequence, a translational enhancer from the 5' leader sequence of alfalfa mosaic virus (5' AMV; Jobling and Gehrke, 1987, *Nature*, 325:622-25), was used to enhance the translation of the mRNA. The RIL gene coding sequence was inserted into the 15 vector behind this 5' AMV sequence (see Fig. 1). This construct, 5' AMV-RIL, was excised by digestion with *Xho*I and *Sac*I and inserted into a binary vector pKLP36 (Maiti and Shepherd, 1998, *Biochem. Biophys. Res. Comm.* 244:440-44), yielding a construct named pKLP RIL. The 20 pKLP36 vector contains the transfer DNA (T-DNA) right and left borders for gene insertion into plant genomes, a NPTII gene (for Kanamycin resistance) as a selectable marker for plant transformation, and the 36S promoter from peanut chlorotic streak caulimovirus and the 3' 25 untranslated sequence from a Rubisco small subunit gene (rbcS3', Fig. 1) to drive the expression of the assembled

RIL gene.

EXAMPLE 15

Assembly of a PreRIL Gene for Secretion of Rev4 in Plants

A secretion signal peptide sequence from tobacco PR-1b (Cornelissen et al., 1986, EMBO J.5:34-40) was added to RIL to facilitate secretion of Rev4 into the extracellular space of plant tissues where invading pathogens might be first encountered. Two primers (GACTGGAGCTCTTAAATAAGAGGCCATTCCAAGGCCACCAAGGCCATCTCCT and AGCTGGGAATTCTAGGAGATGGCCTTGGTGGC) were designed to introduce the signal sequence and preserve the native cleavage site for processing.

The PCR product (67 base pairs) was precipitated and digested with EcoRI and XbaI, then cloned into the pBS plasmid vector already containing the 5' AMV and PR-1b sequences to yield plasmid pBS PreRIL. The sequence identity was confirmed by DNA sequencing. The cassette 5'AMV-PR-1b-RIL was then excised with XhoI and XbaI and inserted into pKLP36 to create pKLPPreRIL.

EXAMPLE 16

Assembly of a Pro-Peptide PPRIL Gene Encoding Rev4 Peptide

Natural peptide hormones are initially synthesized as large prepro-hormone precursors that are

processed to form the smaller active peptides (Hook et al., 1994, FASEB J. 8:1269-78). Pro-sequences can facilitate the trans-membrane movement of peptides and prevent the release of active peptide until it is in the correct cellular compartment. In this example we used a pro-sequence based on that found in natural magainin genes (Zasloff, 1987, PNAS 84:5449-53; ATGGACTCTAGATTAAATAAGAGGCCATTTCCAAGGCCACCAAGGCCATCTCCT) and linked it to Rev4-coding sequence through a His-Ser motif that corresponds to the site at which plant extracellular proteases cleave natural magainins (Everett, 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, Menn & Hollingworth, ACS Symposium Series 551, pp. 278-91). Correct processing at this site should leave an additional Ser residue on the N-terminus of Rev4, a modification that has been shown not to significantly reduce biological activity (Examples 12 and 13). Two oligonucleotide primers (AGCTGGGAATTCTAGGAGATGGCCTTGGTGGC and nucleic acid sequence corresponding to Leu-Pro-Gln-Pro-Glu-Ala-Ser-Ala-Asp-Glu-Gly-Val-Asp-Glu-Arg-Glu-Leu-His^x-Ser were used to generate the full-length gene by PCR as described above in previous Examples.

The PCR product was cloned into the pBS plasmid vector as in Example 15 to yield pBS PPRIL. As before, the gene cassette (5'AMV-PR-lb-Pro-RIL) was then inserted

into pKLP36 as a XhoI/XbaI fragment and named pKLP PPRIL.

EXAMPLE 17

Assembly of PCRIL Gene Encoding Rev4 as a Fusion to a Fragment of PR-lb

5 The unusual amino acid composition and structure of Rev4 and related peptides might interfere with correct peptide secretion or processing if the Rev4 sequence is directly adjacent to the natural signal peptide processing site. This would be similar to the importance of both the
10 transit peptide and the transported protein sequence for protein transport into chloroplasts (Wassman et al., 1986, Mol. Gen. Genet., 205:446-53). Accordingly, PCRIL was designed so that the Rev4 peptide would be fused to the C-terminus of a peptide corresponding to the first 20
15 amino acids of the PR-lb coding sequence, which naturally follows the PR-lb signal sequence. To facilitate release of Rev4 peptide from the PR-lb-Rev4 fusion product, the junction between PR-lb and Rev4 was engineered to include a cleavage site (Ala-Ala-Lys-Ile-) that would be
20 recognized by pepsin-like acid proteases that should not be inhibited by Rev4 (Example 10) and are produced by many fungi (Shintani et al., 1997, J. Biol. Chem. 272:18855-61, Morihara and Oka, 1973, Arch. Biochem. Biophys., 157:561-72).

The DNA encoding PR-lb signal peptide and the first 20 amino acids of the mature PR-lb protein was cloned by PCR from genomic DNA of *Nicotiana tabacum* cv Samsun NN
5 using two oligonucleotide primers (AGCACTGAATTCTCTTCCACAAAC CAGAGGCTTCTGCTGATGAAGGTGTTGATGAAAGAGAGCTCCATTCTAGGAGATGGCC TTGGTGG and GTCACCTGCAGCCACGCCTACATCTGCAC) . To be compatible with the cloning of the PR-lb protein coding sequence, the 5' cloning site of RIL was changed by a PCR
10 reaction using CCAGTCTCTAGAACCATGAGGAGATGGCCTTGG and a new primer, ACGAAGCTTACCATGGGATTTTTCTC. The cloned sequences were verified by DNA sequencing. The DNA and amino acid sequences of this construct are listed in AGTCACTGCAGCTAAGATTAGGAGATGGCCTTGGT and
15 ATGGGATTTTCTCTTCAAAATGCCCTCATTTTCTGTCTACACTCTCT TATTCTAATAATATCTCACTCTCATGCCAAAACTCTCAACAAGACTATTTGGA TGCCCATAACACACAGCTCGTGCAGATGTAGGCGTGGCTGCAGCTAAGATTAGGAGATGG CCTTGGTGGCCTTGGAAATGGCCTTTATTTAA, respectively. The gene cassette PCRIL as shown in Fig. 1 was first assembled in
20 pBS and then moved into pKLP36, as described in previous Examples. The resulting new plasmid was pKLP PCRIL.

EXAMPLE 18

Assembly of pPZP AMY and pPZP APM

In order to test the protective activity of the
25 Rev4 peptide on Myp30 *in vivo*, we have cloned the Myp30

gene into a second binary vector pPZP (Hajdukiewicz et al., 1994, Plant Molecular Biology, 25:989-94) which contains the resistance gene of gentamycin as plant selection marker. This allows us to do a double 5 transformation on the Rev4 containing plants with Myp30 gene as the second transformants can be selected as gentamycin resistance plants.

Myp30 (AMY) and PR-1b-Myp30 (APM) genes were excised as Xhol and SacI fragment from the pBS-AMY and 10 pBS-APM constructs (Li et al., 1999, submitted for publication) and ligated to promoter EMV-FLt-10 in the context of pKYLX (Maiti et al., 1997, Transgenic Research, 6:143-56). Then the promoter, AMY or APM with rbcS 3' UTR sequences were excised out by an EcoRI and Clal (blunted), 15 and ligated to pPZP221 vector (prepared as EcoRI and SmaI cutting), and the resulting plasmids named as pPZP-AMY and pPZP-APM, respectively.

EXAMPLE 19

Production of Polyclonal Antibodies against Rev4

20 The synthetic Rev4 peptide from Example 1 was conjugated with keyhole limpet hemocyanin (Calbiochem, Inc.) following the procedure of Deen et al. (1990, J. Immunol. Methods 129:119-25). The conjugated and non-conjugated peptides were both injected into New Zealand

rabbits as described by Ausubel et al. (1987, Current Protocols in Molecular Biology. Wiley Interscience Press.) After four sets of injections, the sera were collected, 0.01% sodium azide was added, and the sera was
5 stored at -80° C.

EXAMPLE 20

Production of Transgenic Plants Expressing Rev4 Gene Constructs

The research described herein has identified a
10 class of peptides, and their corresponding DNA sequences, that have enhanced stability against plant proteases and which may also stabilize other peptides, polypeptides or proteins against degradation by proteases of plant, fungal, insect or other origins. Agronomic,
15 horticultural, ornamental, and other economically or commercially useful plants can benefit from this invention by introducing these DNAs therein in a functionally operable manner so that they are expressed at a level effective to confer on such transgenic plants improved
20 disease resistance or some other improvement that is conferred by the expression of a peptide related to Rev4.

Because an important use of the invention is to use the introduction of a first gene encoding a Rev4-related peptide to protect the peptide, polypeptide or

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

protein product of a second gene against protease degradation, the second gene may already be present in the plant to be transformed; or the first and second genes may be combined in one plant by sexual hybridization of two 5 independent transformed plants, one containing the first gene and the other containing the second gene; or the two genes may be introduced simultaneously. Furthermore, instead of the gene products of the first and second gene being produced from different transcriptional units that 10 are provided with separate promoters and other gene expression components, the two peptides, polypeptides, or proteins may be produced from a single transcriptional unit under the control of a single promoter. Such single transcriptional unit may represent a dicistronic unit in 15 which the first and second gene sequences are separated by a DNA sequence which allows reinitiation of translation, or it may represent a single translational unit that produces a protein fusion product that comprises the peptide, polypeptide or protein product of the first gene 20 fused to the peptide, polypeptide or protein product of the second gene. Such fusion product may either retain the activity and function of the individual products of the first and second gene, or the two individual products may be released from the fusion by a subsequent cleavage.

25 Transgenic plants that express biologically effective amounts of Rev4 and biologically functional

equivalents thereof can be produced by:

- (a) transforming plant cells with a recombinant DNA molecule comprising operatively linked in sequence in the 5' to 3' direction:
- 5 (i) a promoter region that directs the transcription of a gene in plants,
- (ii) an optional DNA sequence which encodes a signal sequence that directs the sorting of proteins in the secretory system (see for example Chrispeels, 1991,
10 Ann. Rev. Plant Physiol. Plant Mol. Biol. 42:21-53)
- (iii) a DNA coding sequence that encodes an RNA sequence which comprises a sequence which encodes Rev4 having essentially the same or similar biological properties as that of Rev4;
- 15 (iv) an optional DNA sequence which encodes a signal sequence that directs the sorting of proteins in the secretory system (see for example Chrispeels, 1991,
Ann. Rev. Plant Physiol. Plant Mol. Biol. 42:21-53)
- (v) a 3' non-translated region that encodes a polyadenylation signal which functions in plant cells to cause transcriptional termination and the addition of polyadenylate nucleotides to the 3' end of said RNA sequence;

(b) selecting plant cells that have been
transformed

(c) regenerating plant cells that have been
transformed to produce differentiated, fertile, transgenic
5 plants

(d) selecting a transformed plant, cells of
which express said DNA coding sequence and produce a
biologically functionally equivalent thereof.

Methods for transforming a wide variety of
10 dicotyledonous and monocotyledonous plants are well
documented in the literature (see for example U.S. Patent
No. 5,773,696 and references therein). Such methods can
be used by one ordinarily skilled in the art to produce
transgenic plants that express biologically effective
15 amounts of a Rev4-related peptide or biologically
functionally equivalent thereof.

By way of a non-limiting example, the
introduction into tobacco of gene constructs which encode
Rev4-related peptides is described. To enable the use of
20 *Agrobacterium*-mediated transformation, the pKLP constructs
described in Examples 14, 15, 16, and 17 were transferred
from *E. coli* to *Agrobacterium tumefaciens* C58 by a
triparental mating procedure as described by Ditta et al.
(1980, PNAS 77:7347-51).

The *Agrobacterium* containing RIL constructs were then used to transform tobacco (*Nicotiana tabacum* cv KY14) as described by Horsch et al. (1986, PNAS, 83:2571-75). Briefly, sterile leaf discs were co-cultured with the 5 *Agrobacteria* on a non-selective medium (MS agar medium containing 3% sucrose and 2.5 mg/L benzylaminopurine, and 1 mg/L indole-3-acetic acid) for 2 days, followed by continued culture (transferred to fresh medium once a week) on selection medium (same as non-selective one but 10 containing 300 mg/L kanamycin (Sigma, St. Louis) and 500 mg/L mefoxin (Merck and Co., West Point, PA). When the regenerated, kanamycin-resistant plants were at the 3-4 leaf stage, they were transferred to rooting medium (MS agar medium containing 3% sucrose and 500 mg/L mefoxin) 15 for root induction. Plantlets with roots were transplanted to soil and grown to maturity in a standard greenhouse.

The same set of *Agrobacteria* was used to transform *Arabidopsis thaliana* ecotype Columbia by a 20 vacuum infiltration protocol (Bent et al., 1994, Science 265:1856-60). Briefly, flowering *Arabidopsis* plants were dipped into the *Agrobacteria* suspension, then vacuum was applied for 3 minutes. The seeds from the treated plants 25 were harvested and screened on appropriate selection markers (kanamycin or gentamycin both in 50 mg/l). Double transformation of pKLP and pPZP constructs in *Arabidopsis*

were generated by transforming pPZP containing *Agrobacteria* to already transformed pKLP RIL, PCRIL PPRIL and PrcRIL *Arabidopsis* plants.

EXAMPLE 21

5 Detection of Rev4 mRNA in Transgenic Plants

Because the level of expression of a transgene can vary considerably between different transformation events, it is useful to categorize transformants into high, medium, or low expressors in preparation for further analysis. Total RNA was isolated from the leaves of 7 to 8 week old transgenic plants using the RNAqueous phenol-free total RNA isolation kit (Ambion Inc., Austin, Texas). Equal amounts of total RNA (10 µg) from individual transformants were separated on a 1.2% agarose gel, transferred to Nytran (Schleicher & Schell, Keene, NH), hybridized with a ³²P-labeled RIL DNA probe, and washed using standard protocols (Sambrook et al., 1989, Molecular Cloning, a Laboratory Manual. Cold Spring Harbor Laboratory Press.). The blots (not shown) were visualized by autoradiography and phosphor imager (Fujifilm Fluorescent Image Analyzer FLA-2000, Fuji, Japan).

EXAMPLE 22

Detection of Increased Bacterial Pathogen Resistance in

Transgenic Plants

Leaf tissue (300 mg) was collected from leaves of young plants (4-6 leaf stage) and homogenized in 200 μ L of 2x SDS-PAGE sample buffer (0.125 M Tris HCl, pH 6.8,
5 20% [v/v] glycerol, 2% [w/v] SDS, 10% [v/v] beta-mercaptoethanol, and 0.001% [w/v] bromophenol blue) using a mortar and pestle. The samples were boiled for 10 minutes, centrifuged to pellet cell debris, and the supernatant stored at -20° C for future analysis.

10 For immunoblot analysis, the proteins from 30 mg of leaf tissue were separated by 16.5% Tris-Tricine SDS-PAGE (Schagger and Jagow, 1987, Anal. Biochem. 166:368-79, precast gels from Bio-Rad Laboratories) and transferred to a nitrocellulose membrane using a Trans Blot Cell (Bio-Rad
15 Laboratories) following the manufacturer's recommendations. Filters were probed with polyclonal antibodies specific for the Rev4 peptide (Example 18). Briefly, filters containing transferred proteins were incubated at room temperature in TTBS (20 mM Tris-HCl, pH
20 7.5, 0.5 M NaCl, 0.05% [v/v] Tween 20, 3% [w/v] nonfat dried milk) for 30 minutes, followed by incubation with the Rev-4 specific antibodies for 1 hour in the same buffer. After the excess antibodies were removed with four washes (5 minutes each) of TTBS, the filters were
25 incubated for 30 minutes with 3% milk-TTBS containing

peroxidase-conjugated goat antirabbit IgG (Jackson Immuno Research Laboratories, Inc., West Grove, PA). The excess second antibody was removed with four washes of TTBS and two washes of water. Filters were then developed with 5 Chemilumuniscence Reagent Plus Kit (DuPont NEN Research Products, Boston, MA), and the resulting chemiluminescence detected by exposure to photographic film.

The expression of RIL genes in transgenic plants can also be detected using phenotypic analyses such as 10 increased disease resistance or any other convenient phenotype that results from the biological properties of Rev4-related peptides in combination with a second biologically active peptide, polypeptide or protein.

EXAMPLE 23

15 Detection of Increased Bacterial Pathogen Resistance in Transgenic Plants

Increases in bacterial disease resistance can be performed in progeny of the primary transformants. A tobacco bacterial pathogen, *Erwinia carotovora* subsp. 20 *carotovora* (Pirhonen et al., 1991, Molecular Plant-Microbe interactions, 4:276-83) was used for the testing of tobacco plants. The overnight culture of the bacteria was centrifuged (1,000 x g) and the pellet resuspended in sterile water until a solution with an OD₆₀₀-0.8 was

obtained. Two μ l of the bacterial suspension were dropped onto an extended leaf of individual tobacco seedlings (5-6 weeks old) grown in a 24-well microtiter plate in MS medium. The tobacco seedlings were cultured in a growth chamber 23-24°C, with 10 hours light/14 hours dark period.

Individual experiments consisted of 8 plants per replication and at least 6 replications for each transgenic line. After 14 days, the number of dead plants was recorded.

Plant Line Code	% Plants Surviving <i>Erwinia carotovora</i> Test
KYLX (Control)	16
RIL 26	48
PCRIL 24	36
PCRIL 26	61

Table *Erwinia carotovora* resistance tests of Rev4 transgenic tobacco plants. Two μ l of a bacterial suspension were inoculated onto the leaf of each tobacco seedling (4 weeks old), cultured in 24-well plates containing MS medium. Each test involved 8 replications of 6 plants for each transgenic line and the KYLX control.

For testing bacterial resistance of Rev4 transformed *Arabidopsis*, *Pseudomonas syringae* pv. *maculicola* ES4326 was used. An overnight culture of the bacteria was spun down and resuspended in 10 mM MgSO₄ with Silwet 1-77 (200 μ l/liter), to make OD₆₀₀-0.001. Four week-old *Arabidopsis* plants (grown at 8 hours light/16 hours dark, 23° C) were dipped in the bacterial solution,

briefly drained and returned to the growth chamber. After 4 days, pictures were taken and the average infected leaves in each group were grounded and spread on LB medium for bacteria counting.

5 EXAMPLE 24

Detection of Increased Fungal Pathogen Resistance in Transgenic Plants

Tobacco blue mold (*Peronospora tabacina*) was used to test transgenic tobacco plants for increased 10 disease resistance to this fungal pathogen. Tobacco leaf panels (8 panels per leaf, one leaf per plant of the same age, and three plants of each line) were infiltrated with 100 spores in water solution (10 μL). After 7 days, the total infected area on the individual leaves was measured. 15 The reduction of the disease severity was calculated as percentage of that seen with a water control.

For the fungal resistance of *Arabidopsis* Rev4 transgenic plants, *Peronospora parasitica* var. Noco 2 was used to the testing. The active spores of the fungus (in 20 water, 50,000 spores/ml) was sprayed on the 2 week-old *Arabidopsis* seedlings. After 6 days, the symptoms were recorded by photograph. The growth condition of the *Arabidopsis* plants were the same as in Example 22.

PLANT LINE	AVERAGE NO. SPORES x 10 ³ /cm ²	STANDARD DEVIATION
KIX (control)	274	77
ril 24	169	43
pcril 24	169	65
pcril 26	135	31

SEQUENCE LISTING

SEQ. ID NO. 1 (24 amino acids) [MYP30]

Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys
5 Phe Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro

SEQ. ID NO. 2 (13 amino acids) [indolicidin
(amide)]

Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg
Arg

10 SEQ. ID NO. 3 (13 amino acids) [CP-11]

Ile Leu Lys Lys Trp Pro Trp Trp Pro Trp Arg Arg
Lys

SEQ. ID NO. 4 (13 amino acids) [Rev4 (amide)]

Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu
15 Ile

SEQ. ID NO. 5 (14 amino acids) [Ser-Rev4-OH]

Ser Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro

Leu Ile

SEQ. ID NO. 6 (26 amino acids) [Rev4-C-fusion]

Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu
Ile Gly Gly Gly Tyr Asp Pro Ala Pro Pro Pro Pro Pro

5 SEQ. ID NO. 7 (13 amino acids) [Indolicidin F
(amide)]

Ile Leu Pro Phe Lys Phe Pro Phe Phe Pro Phe Arg
Arg

10 SEQ. ID NO. 8 (12 amino acids) [Indolicidin F-P
(amide)]

Ile Leu Lys Gly Phe Pro Gly Phe Pro Arg Arg Lys

SEQ. ID NO. 9 (21 amino acids) [reverse PGLc]

Leu Ala Lys Leu Ala Val Lys Ala Ile Lys Gly Ala
Ile Ala Gly Ala Lys Ser Ala Met Gly

15 SEQ. ID NO. 10 (31 amino acids) [reverse
cecropin P1]

Arg Pro Gly Gly Gln Ile Ala Ile Ala Ile Gly Glu
Ser Ile Arg Lys Lys Ala Ser Asn Glu Leu Lys Lys Ala Thr
Lys Ser Leu Trp Ser

20 SEQ. ID NO. 11 (37 amino acids) [reverse

cecropin A amide]

Lys Ala Ile Gln Thr Ala Gln Gly Val Val Ala Val
Ala Pro Gly Ala Lys Ile Ile Gly Asp Arg Ile Asn Gln Gly
Val Lys Glu Ile Lys Lys Phe Leu Lys Trp Lys

5 SEQ. ID NO. 12 (27 amino acids) [reverse
bombinin-like peptide amide]

Asn Ala Phe His Glu Ala Leu Gly Lys Ala Leu Gly
Lys Leu Ala Ser Lys Gly Ala Ser Leu Ile Ser Ala Gly Ile
Gly

10 SEQ. ID NO. 13 (23 amino acids) [Magainin 2]

Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe
Gly Lys Ala Phe Val Gly Glu Ile Met Asn Ser

SEQ. ID NO. 14 (RIL)

Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-
15 Ile

SEQ. ID NO. 15 (RIL Coding)

AGGAGATGGCCTTGGTGGCCTTGGAAATGGCCTTTATT

SEQ. ID NO. 16 (primer RIL 5' XbaI)

CCAGTCTCTAGAACCATGAGGAGATGGCCTTGG

20 SEQ. ID NO. 17 (primer RIL 3' SacI)

GACTGGAGCTCTTAAATAAGAGGCCATTCCAAGGCCACCAAGGCCAT

CTCCT

SEQ. ID NO. 18 (primer RIL5' EcoRI)

AGCTGGGAATTCTAGGAGATGGCCTTGGTGGC

5 SEQ. ID NO. 19 (primer RIL 3' XbaI)

ATGGACTCTAGATTAAATAAGAGGCCATTCCAAGGCCACCAAGGCCA

TCTCCT

SEQ. ID NO. 20 (Pro)

Leu-Pro-Gln-Pro-Glu-Ala-Ser-Ala-Asp-Glu-Gly-Val-

10 Asp-Glu-Arg-Glu-Leu- His*-Ser

SEQ. ID NO. 21 (primer PRIL 5')

AGCACTGAATTCTCTCCACAACCAGAGGCTTGCTGATGAAGGTGT

TGATGAAAGAGAGCTCCATTCTAGGAGATGGCCTTGGTGG

SEQ. ID NO. 22 (primer cPR1b 3'PstI)

GTCACCTGCAGCCACGCCTACATCTGCAC

15 SEQ. ID NO. 23 (primer PR-1b 5' HindIII/NcoI)

ACGAAGCTTACCATGGGATTTTCTC

SEQ. ID NO. 24 (primer RIL5' PstI)

AGTCACTGCAGCTAACGATTAGGAGATGGCCTTGGTG

SEQ. ID NO. 25 (PCRIL DNA coding sequence)

ATGGGATTTTCTCTTACAAATGCCCTCATTTTCTGTCTCT
ACACTTCTCTTATTCTAATAATATCTCACTCTCATGCCAAA
ACTATTTGGATGCCATAAACACAGCTCGTAGGCAGCTGCAGCTAAGAT
5 TAGGAGATGCCCTGGTGGCCTGGAAATGCCCTTATTAA

SEQ. ID NO. 26 (full sequence of PCRIL)

Met Gly Phe Phe Leu Phe Ser Gln Met Pro Ser Phe
Phe Leu Val Ser Thr Leu Leu Phe Leu Ile Ile Ser His
Ser Ser His Ala* Gln Asn Ser Gln Gln Asp Tyr Leu Asp Ala
10 His Asn Thr Ala Arg Ala Asp Val Gly Val Ala Ala Ala
Lys#Ile Arg ArgTrp Pro Trp Trp Pro Trp Lys Trp Pro Leu
Ile

* and # are the PR-1b signal peptide and PR-1b
coding cleavage site, respectively. The RIL peptide
15 sequence is underlined.

We claim:

1. A method for reducing the extent of protease degradation of a protein applied to or produced by a plant comprising administering to the plant or a part 5 thereof a peptide comprising indolicidin, Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile (Rev4) or a functional equivalent thereof.

2. The method of claim 1 wherein said functional equivalent comprises the formula:

10 X-X-Y-Y-Y-Y-Y-X-Y-Y-Y; or

Y-Y-Y-Y-X-Y-Y-Y-Y-Y-X-X

wherein each X is independently arginine, lysine or histidine; and

15 wherein each Y is independently tryptophan, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.

3. The method of claim 1 wherein said peptide is Ser-Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile (Ser-Rev4-OH).

20 4. The method of claim 1 wherein said peptide is Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile-Gly-Gly-Gly-Tyr-Asp-Pro-Ala-Pro-Pro-Pro-Pro-Pro (Rev4-

C-Fusion).

5. The method of claim 1 wherein said protein
is an antipathogenic agent.

6. The method of claim 5 wherein said protein
5 is an antibacterial agent

7. The method of claim 5 wherein said protein
is an antifungal agent.

8. The method of claim 5 wherein said protein
is an antiviral agent.

10 9. The method of claim 5 wherein said protein
is an insecticidal agent.

10. The method of claim 1 wherein said protein
is selected from the group consisting of Magainins,
reverse Magainins, PGLc, reverse PGLc, PI's, reverse PI's,
15 Cecropins, reverse Cecropins, Sarcotoxins, reverse
Sarcotoxins, Bombinins, reverse Bombinins, XPFs, reverse
XPF's, Thionins, reverse Thionins, Defensins, reverse
Defensins, Melittins, reverse Melittins, PGL a, and
reverse PGLa, Dermaseptins, reverse Dermaseptins,
20 Histatins, reverse Histatins, peptides derived from pig
myeloid cells, peptides derived from human neutrophil
cathepsin G, antimicrobial peptides from bovine
neutrophils, Seminalplasmin, antimicrobial derived from

Lactoferrin, Drosocin, Tachyplesins, reverse Tachyplesins, Maize Basic Peptide I, Tracheal antimicrobial peptides, Antimicrobial peptides from seeds of amaranth, antimicrobial peptides from seeds of *Mirabilis jalapa*,
5 Ranalexin, Brevenin, Subtilin, Nisin, Epidermin, Lactacin 481, and basic amphipathic peptides.

11. The method of claim 1 wherein said protein is selected from the group consisting of enzymes, pharmaceuticals, agricultural products, feed additives or
10 food additives.

12. The method of claim 1 wherein said peptide is Rev4 and said protein is selected from the group consisting of Magainins and reverse Magainins.

13. The method of claim 1 wherein said administering comprises transforming said plant or part thereof with an non-native DNA comprising a sequence encoding said peptide.
15

14. The method of claim 1 wherein said administering comprises spraying said plant or part thereof with a composition comprising said peptide functional equivalent.
20

15. The method of claim 14 wherein said composition further comprises said protein.

16. The method of claim 14 wherein said spraying said plants or parts thereof is conducted after said plant or part thereof is harvested.

17. The method of claim 14 wherein said spraying said plants or parts thereof is conducted during processing or formulation of said plant or part thereof.

18. The method of claim 1 wherein said protease is a plant protease.

19. The method of claim 1 wherein said protease is a bacterial protease.

20. The method of claim 1 wherein said protease is a viral protease.

21. The method of claim 1 wherein said protease is a fungal protease.

15 22. The method of claim 1 wherein said protease is an insect protease.

23. The method of claim 1 wherein said plant or part thereof is selected from the group consisting of maize, tomato, turfgrass, asparagus, papaya, sunflower, rye, beans, ginger, lotus, bamboo, potato, rice, peanut, barley, malt, wheat, alfalfa, soybean, oat, eggplant, squash, onion, broccoli, sugarcane, sugar beet, beets, apples, oranges, grapefruit, pear, plum, peach, pineapple,

grape, rose, carnation, daisy, tulip, Douglas fir, cedar, pine, spruce, peas, cotton, flax, coffee and tobacco.

24. The method of claim 1 wherein said peptide is fused with at least one other peptide.

5 25. The method of claim 1 wherein said peptide is conjugated with at least one other peptide.

10 26. The method of claim 1 wherein said peptide is administered by applying said peptide to said plant or part thereof and said peptide is crosslinked with at least one other peptide.

27. A method of inhibiting the growth of a plant pathogen comprising administering to a plant or part thereof Rev4 or a functional equivalent thereof.

15 28. A peptide comprising Rev4 (Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile) or a functional equivalent thereof.

29. A nucleic acid molecule comprising a sequence encoding Rev4 (Arg-Arg-Trp-Pro-Trp-Trp-Lys-Trp-Pro-Leu-Ile) or a functional equivalent thereof.

20 30. The nucleic acid molecule of claim 29 comprising AGGAGATGGCCTTGGTGGCCTTGGAAATGGCCTCTTATT or a complement thereof.

31. The nucleic acid molecule of claim 29 which is DNA.

32. The nucleic acid segment of claim 29 which is RNA.

5 33. A nucleic acid construct, comprising from 5' to 3', a transcriptional initiation region functional in plants, a nucleic acid sequence encoding Rev4 or a functional equivalent thereof, and a transcriptional termination sequence.

10 34. The nucleic acid construct of claim 33 further comprising a regulatory nucleic acid sequence.

 35. The nucleic acid construct of claim 33 further comprising a reporter gene.

15 36. A transgenic plant comprising a nucleic acid including a sequence encoding Rev4 or a functional equivalent thereof.

 37. The transgenic plant of claim 36 wherein said sequence encodes a functional equivalent of Rev4 comprising the formula:

20 X-X-Y-Y-Y-Y-Y-X-Y-Y-Y-Y

 wherein each X is independently arginine, lysine or histidine; and

wherein each Y is independently tryptophan, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.

38. The transgenic plant of claim 36 further
5 comprising at least one nucleic acid sequence encoding a protein of agronomic interest.

39. A method of making a plant, comprising preparing a plant having a genome that contains a DNA sequence encoding Rev4 or a functional equivalent thereof
10 wherein said sequence is expressed.

40. The method of claim 39 comprising stably transforming a protoplast with said DNA molecule, and generating the plant from the transformed protoplast.

41. The method of claim 39 comprising introducing the DNA molecule into plant tissue, and regenerating the plant tissue containing the DNA molecules.
15

42. The method of claim 39 wherein said plant further contains a DNA sequence encoding a protein of
20 agronomic interest.

43. A seed derived from the plant of claim 36.


44. A plant cell comprising a nucleic acid sequence encoding Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-

Pro-Leu-Ile (Rev4) or a functional equivalent thereof.

45. The plant cell according to claim 44 further comprising a nucleic acid sequence encoding an agronomic protein of interest.

5 46. A composition for use in protecting a peptide, polypeptide or protein from protease degradation, comprising Rev4 or a functional equivalent thereof and a carrier.

10 47. The composition of claim 46 wherein said functional equivalent comprises the formula:



wherein each X is independently arginine, lysine or histidine; and

15 wherein each Y is independently tryptophan, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.

48. The composition of claim 47 further comprising a protein of agronomic interest.


ABSTRACT

Disclosed are peptides that have enhanced stability against plant proteases and are useful in the control of plant diseases. The peptides also have the 5 ability to protect other peptides, polypeptides or proteins from degradation by proteases of plant, fungal, viral, bacterial, insect or other origin. DNA encoding the peptides of the present invention can be co-expressed with other DNA encoding exogenous peptides in transgenic 10 plants as a method for protecting foreign peptides from degradation by proteases. Also disclosed are nucleic acid sequences, microorganisms, plants, and compositions useful for the treatment of plant diseases.

225573_1.DOC

FIG. 1

RIL gene constructs



Abreations:

RIL: reverse indolicidin; PR-1b sp, Pathogen related protein 1b signal peptide; PR-1b cr, PR-1b coding region; Pro, the modified pro sequence of Magainin; PCISV, duplicated promoter from peanut chlorotic streak caulimovirus; 5' AMV, the leader sequence of alfalfa mosaic virus; rbcS3', 3' untranslated region of rubisco small subunit gene; NPTII, the gene confer Kanamycin resistance in plant; T_L and T_R, the T-DNA left and right border, respectively; Kan^r and Tet^r, Kanamycine and tetracycline resistance gene, respectively; ori, the origin for DNA replication.

FIG. 2




FIG. 3

Lines	% surviving plants
KYLX	0.16
RIL 26	0.48
PCRIL 24	0.36
PCRIL 26	0.61




Fig 3. *Erwinia carotovara* resistance tests of Rev4 tobacco transgenic plants. Two μ l of a bacterial suspension were inoculated onto the leaf of each tobacco seedling (4 weeks old), cultured in 24-well plates containing MS medium. 8 replications of 6 plants for each transgenic line and controls were tested.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

ATTORNEY'S DOCKET NO.: INTERLINK 3.0-003

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PEPTIDES WITH ENHANCED STABILITY TO PROTEASE DEGRADATION the specification of which

is attached hereto

was filed on _____ as United States Application Number or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.3(d).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING (month, day, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
			YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
			YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>

LISTING OF FOREIGN APPLICATIONS CONTINUED ON PAGE 3 HEREOF YES NO

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Application Number: 60/106,373 Filing Date: October 30, 1998

Application Number: 60/106,573 Filing Date: November 2, 1998

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(b) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Parent Application Serial Number:

Parent Filing Date:

Parent Patent No.:

U.S. Parent Application Serial Number:

Parent Filing Date:

Parent Patent No.:

PCT Parent Number:

Parent Filing Date:

LISTING OF US APPLICATIONS CONTINUED ON PAGE 3 HEREOF: YES NO

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Lawrence J. Lerner, Reg. No. 19,516; Sidney David, Reg. No. 22,768; Joseph S. Littenberg, Reg. No. 28,482; Arnold H. Krumholz, Reg. No. 28,498; William L. Mentlik, Reg. No. 27,168; John R. Nelson, Reg. No. 28,573; Roy H. Weisner, Reg. No. 28,610; Stephen B. Goldstein, Reg. No. 28,611; Mark J. Miller, Reg. No. 28,641; Bruce H. Salas, Reg. No. 32,748; Daniel H. Bobis, Reg. No. 35,661; Karen E. Gilman, Reg. No. 39,137; Robert B. Cohen, Reg. No. 39,766; Arnold B. Danzig, Reg. No. 40,766; Michael H. Tischman, Reg. No. 42,922; Gregory S. Cowitz, Reg. No. 56,829; Jonathan A. Davis, Reg. No. 56,194; Steven P. Polley, Reg. No. 58,671; John P. Mandler, Reg. No. 47,887; Thomas M. Palley, Reg. No. 34,626; Kimberly V. Perry, Reg. No. 42,812; Jason L. Garbell, Reg. No. 44,113; Renée M. Roberts, Reg. No. 41,777; Raymond W. Augustin, Reg. No. 38,088; Harvey L. Cohen, Reg. No. 38,503; Michael J. Wallace, Jr., Reg. No. 46,486; Michael J. Donnelly, Reg. No. 46,086; Robert J. Gureff, Reg. No. 46,086; Jeffrey S. Disney, Reg. No. 34,868.

SEND CORRESPONDENCE TO:
**LERNER, DAVID, LITTENBERG,
 KRUMHOLZ & MENTLIK, LLP**
600 South Avenue West
Westfield, New Jersey 07090

DIRECT TELEPHONE CALL TO:
 (name and telephone number)

JASON I. GARBELL
 (908) 654-5000 Fax: (908) 654-7866

DECLARATION -- Page 2

ATTORNEY DOCKET NO. INTERLINK 3.0-005

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name): NICHOLAS P. EVERETT

Inventor's signature _____ Date _____

Residence: MEADOW VISTA, CA 95722 Citizenship: United Kingdom

Post Office Address: 604 Apple Tree Lane, Meadow Vista, CA 95722

Full name of second joint inventor, if any (given name, family name): QUNIGSHUN LI

Second Inventor's signature Qunigshun Li Date Oct 29, 1999

Residence: LEXINGTON, KY 40515 Citizenship: Peoples Republic of China

Post Office Address: 2268 Cambreling Drive, Lexington, KY 40515

Full name of third joint inventor, if any (given name, family name): CHRISTOPHER LAWRENCE

Third Inventor's signature Christopher Lawrence Date 10/29/99

Residence: LEXINGTON, KY 40503 Citizenship: United States of America

Post Office Address: 625 Sheridan Drive, Lexington, KY 40503 *fwd*

Full name of fourth joint inventor, if any (given name, family name): MAELOR H. DAVIES

Fourth Inventor's signature Maelor Davies Date 10/29/99

Residence: LEXINGTON, KY 40515 Citizenship: United States of America

Post Office Address: 2137 Leafland Place, Lexington, KY 40515

Full name of fifth joint inventor (given name, family name):

Fifth Inventor's signature _____ Date _____

Residence: Citizenship:

Post Office Address:

Full name of sixth joint inventor, if any (given name, family name):

Sixth Inventor's signature _____ Date _____

Residence: Citizenship:

Post Office Address:

Full name of seventh joint inventor, if any (given name, family name):

Seventh Inventor's signature _____ Date _____

Residence: Citizenship:

Post Office Address:

Full name of eighth joint inventor, if any (given name, family name):

Eighth Inventor's signature _____ Date _____

Residence: Citizenship:

Post Office Address:

Additional inventors are being named on separately numbered sheets attached hereto.

DECLARATION -- Page 2**ATTORNEY DOCKET NO. INTERLINK 3.0-003**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name): **NICHOLAS P. EVERETT**Inventor's signature Nicholas P. Everett Date 10/29/99Residence: MEADOW VISTA, CA 95722 Citizenship: United Kingdom
Post Office Address: 604 Apple Tree Lane, Meadow Vista, CA 95722Full name of second joint inventor, if any (given name, family name): **QUNIGSHUN LI**

Second Inventor's signature _____ Date _____

Residence: LEXINGTON, KY 40515 Citizenship: Peoples Republic of China
Post Office Address: 2268 Cambreling Drive, Lexington, KY 40515Full name of third joint inventor, if any (given name, family name): **CHRISTOPHER LAWRENCE**

Third Inventor's signature _____ Date _____

Residence: LEXINGTON, KY 40503 Citizenship: United States of America
Post Office Address: 625 Sheridan Drive, Lexington, KY 40503Full name of fourth joint inventor, if any (given name, family name): **MAELOR H. DAVIES**

Fourth Inventor's signature _____ Date _____

Residence: LEXINGTON, KY 40515 Citizenship: United States of America
Post Office Address: 2137 Leafland Place, Lexington, KY 40515

Full name of fifth joint inventor (given name, family name):

Fifth Inventor's signature _____ Date _____

Residence: Citizenship:
Post Office Address:

Full name of sixth joint inventor, if any (given name, family name):

Sixth Inventor's signature _____ Date _____

Residence: Citizenship:
Post Office Address:

Full name of seventh joint inventor, if any (given name, family name):

Seventh Inventor's signature _____ Date _____

Residence: Citizenship:
Post Office Address:

Full name of eighth joint inventor, if any (given name, family name):

Eighth Inventor's signature _____ Date _____

Residence: Citizenship:
Post Office Address: Additional inventors are being named on separately numbered sheets attached hereto.